Five of the major AI chatbots were tested. All of them regularly proposed dietary plans akin to skipping an entire meal each day.
An old anti-seizure drug might also work to reduce apnea episodes, recent trial data has shown.
The FDA ultimately ruled against approving leucovorin for autism, citing a lack of "sufficient data."
A new study found that above-ground temperatures directly influence subway passengers' complaints about uncomfortably high below-ground temperatures.
The blood biomarker p-tau217 has "shown the most promise in detecting Alzheimer's in the brain," researchers of a new study say.
The companies' new partnership could signal the beginning of the end for compounded GLP-1s.
New research bolsters the idea that a once-daily supplement can cause real improvements to our rate of aging.
Researchers have found evidence the rat lungworm is now endemic in southern California
Acetaminophen use among pregnant women in the ER dropped following the White House's autism announcement last September.
The discovery could introduce new ways of preventing some of the most severe allergic reactions.
The findings suggest that tapering could help GLP-1 users reduce their medical bills while maintaining their weight loss.
At least 61 of the made-up case reports were unwittingly cited in other peer-reviewed medical journals, creating hundreds more errors.
Over a five-year span, women who used complementary and alternative medicine had a greater mortality rate than those who relied on traditional care.
The health secretary recently announced his plans to have companies like Dunkin' Donuts prove their foods are safe to eat.
New trial results highlight the potential of pairing GLP-1 therapy with muscle-boosting drugs.
Researchers in Finland have found "robust evidence" of a link between pollen and worse academic performance.
RFK Jr. plans to reverse a sweeping compounding ban of certain peptides issued by the FDA in late 2023.
While most people may recover, millions of Americans still had long covid as of 2024, new research estimates.
This week, Lockout Supplements issued a voluntary recall of its "Boner Bears Chocolate Syrup" for having unlabeled amounts of sildenafil.
In a Phase I trial, the treatment appeared to be safe in children with spina bifida.
